JUVE Patent

Daniel is a partner in Kirkland’s IP Litigation Team in London. Daniel has a broad practice which covers a wide range of technical fields and is noted not only for his extensive experience in cutting edge life science patent litigation but also his success in representing clients involved in complex SEP and FRAND licensing disputes.

In addition to UK litigation, Daniel is regularly called upon to assist clients in devising, coordinating and executing patent strategies for complex multijurisdictional disputes at a pan-European and global scale. With dual qualifications in law and biochemistry, and experience litigating across the world, Daniel is readily able to grasp highly technical material and the international dimensions of disputes, which are often at the heart of effective strategies in strategically critical litigation for the most sophisticated clients. In recognition of his experience and leadership in the life sciences field, Daniel currently serves as the Vice-Chair of AIPPI’s standing committee on biotechnology.

Daniel has developed a particular interest and focus in the rising gene editing technology CRISPR, and is recognised as a thought leader and regular writer, speaker and commentator on the topic. Daniel’s previous case experience covers a broad range of technical fields, including dynamic scheduling and resource allocation in radio networks, time division multiple access (TDMA) radio signaling, voltage regulation in integrated circuits, laser engineering, oncology, immunology, neurology, ophthalmology, molecular diagnostics, formulation science, pharmacokinetics, clinical pharmacology and biostatistics.

Daniel has been described in IAM Patent 1000 as a “Life sciences genius with the ability to quickly unpick the most arcane biochemistry issues.”